To the best of our knowledge, this is the first systematic review and meta-analysis to evaluate the effect of SGLT2 inhibitors in the prevention of heart failure and cardiac outcomes in patients with cancer treated with anthracycline. The gene discussed is SLC5A2; the disease is cancer.